RecruitingPhase 2NCT06277791

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

A Single Arm, Exploratory Clinical Study of the Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma in Clinical Practice

Sponsor

Hospital of Stomatology, Wuhan University

Enrollment

35 participants

Start Date

Aug 19, 2023

Study Type

INTERVENTIONAL

Conditions

Clinical IVb Stage Oral Squamous Cell Carcinomas Patients

Summary

The goal of this \[type of study:clinical trial\] is to \[learn about\] in \[Clinical IVB stage oral squamous cell carcinoma patients\]. The main question it aims to answer are: • \[Observing the effectiveness and safety of the combination of Adebrelimab and TP regimen in neoadjuvant therapy for clinical IVB stage oral squamous cell carcinoma patients\] Participants will \[Received treatment with Adebrelimab combined with TP regimen, followed by surgery after 2 cycles of neoadjuvant therapy. After surgery, radiotherapy and chemotherapy combined with immunotherapy were chosen based on the patient\'s condition, with a total follow-up of two years.\].

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of immunotherapy (adebrelimab) plus chemotherapy (cisplatin and paclitaxel) as treatment before surgery (neoadjuvant therapy) for patients with Stage IVB oral squamous cell carcinoma — a type of mouth cancer that has spread to nearby lymph nodes. **You may be eligible if...** - You are diagnosed with oral squamous cell carcinoma at Stage IVB (confirmed by biopsy) - You have not received any prior treatment for this cancer - Your general health and organ function are within acceptable ranges - You are willing to use contraception throughout treatment and for 6 months after **You may NOT be eligible if...** - You have uncontrollable fluid buildup around the lungs or heart - You have active autoimmune disease or prior organ transplant - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdebrelimab

Adebrelimab：20mg/kg, ivdrip, D1，Q3W

Locations(1)

School of Stomatology Wuhan University

Hubei, Wuhan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06277791